Bergen, Norway 21 April 2022
Today, Lifecare 2021 annual report is published. 2021 was marked by several important milestones:
- Regulatory approval for first-in-human pilot clinical trials
- Restructuring the organization – controlling development operations
- Reinforced Patent Protection and IP
- Successful Capital Increase
The report is subject to approval by the company’s general meeting on 6 May 2022.
Lifecare AS’ management team will host an online presentation of the 2021 annual results today at 13:00 – 14:00 CET. The presentation will also include development outlook and assumptions related to the patient and market potential for Sencell. The report and the presentation are attached to this release and are also available on Lifecare’s website. The basis for the Sencell market potential can be downloaded at https://lifecare.no/publications/sencell-market-assumptions-and-commercial-potential-april-2022/ There will be a Q&A session following the management presentation.
The link to the webcast will be available in the Investors section: https://lifecare.no/events/webcast-annual-report-2021/. You can post questions during the event or send them in advance to: email@example.com
Joacim Holter, CEO, Lifecare AS, firstname.lastname@example.org, +47 40 05 90 40
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 21 April 2022 at 11:00 CET.